Suppr超能文献

西乐欣长期用于焦虑症患者的真实世界疗效:单中心经验

Real-world outcomes of long-term use of silexan in patients with anxiety disorders: a single-centre experience.

作者信息

Marchevsky Sergio

机构信息

Beer Yaakov MHC Day Center, Tel Aviv, Israel.

出版信息

Int J Psychiatry Clin Pract. 2024 Jun;28(2):138-141. doi: 10.1080/13651501.2024.2391301. Epub 2024 Aug 18.

Abstract

OBJECTIVE

To evaluate the effectiveness and safety of long-term use of silexan in patients with a wide range of anxiety disorders.

METHODS

A retrospective chart review was conducted on 50 patients diagnosed with various anxiety disorders who were prescribed silexan. The primary outcomes measured included the resolution of anxiety symptoms, changes in Generalized Anxiety Disorder-7 (GAD-7) scores, and Clinical Global Impressions-Improvement (CGI-I) scores. The duration of silexan use and any reported adverse events were also recorded.

RESULTS

Silexan effectively resolved anxiety symptoms in 35 patients, with 24 out of 25 patients who received silexan for more than 12 weeks showing significant improvement. Median GAD-7 and CGI-I scores decreased significantly (p<0.001). By the end of the follow-up period, 46% of patients had minimal anxiety and 24% had mild anxiety. No adverse events were reported during the study period.

CONCLUSIONS

Long-term use of silexan is feasible, safe, and effective in managing a wide range of anxiety disorders in real-world clinical settings.

摘要

目的

评估长期使用西乐葆治疗广泛焦虑症患者的有效性和安全性。

方法

对50例被诊断为各种焦虑症并开具西乐葆处方的患者进行回顾性病历审查。测量的主要结果包括焦虑症状的缓解、广泛性焦虑障碍-7(GAD-7)评分的变化以及临床总体印象改善(CGI-I)评分。还记录了西乐葆的使用时长和任何报告的不良事件。

结果

西乐葆有效缓解了35例患者的焦虑症状,25例接受西乐葆治疗超过12周的患者中有24例显示出显著改善。GAD-7和CGI-I评分中位数显著下降(p<0.001)。随访期末,46%的患者焦虑程度最低,24%的患者有轻度焦虑。研究期间未报告不良事件。

结论

在现实临床环境中,长期使用西乐葆治疗广泛焦虑症是可行、安全且有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验